Multisequence MRI-based radiomics model for predicting POLE mutation status in patients with endometrial cancer
The British Journal of Radiology · 2023
DOI: 10.1259/bjr.20221063 ↗Kurz gefasst
Fachartikel in der Zeitschrift The British Journal of Radiology, 2023. Verfasst von Zijing Lin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Jinshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Endometrial Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objectives
Preoperative identification of POLE mutation status would help tailor the surgical procedure and adjuvant treatment strategy. This study aimed to explore the feasibility of developing a radiomics model to pre-operatively predict the pathogenic POLE mutation status in patients with EC.
Methods
The retrospective study involved 138 patients with histopathologically confirmed EC (35 POLE-mutant vs 103 non-POLE-mutant). After selecting relevant features with a series of steps, three radiomics signatures were built based on axial fat-saturation T2WI, DWI, and CE-T1WI images, respectively. Then, two radiomics models which integrated features from T2WI + DWI and T2WI + DWI+CE-T1WI were further developed using multivariate logistic regression. The performance of the radiomics model was evaluated from discrimination, calibration, and clinical utility aspects.
Results
Among all the models, radiomics model2 (RM2), which integrated features from all three sequences, showed the best performance, with AUCs of 0.885 (95%CI: 0.828–0.942) and 0.810 (95%CI: 0.653–0.967) in the training and validation cohorts, respectively. The net reclassification index (NRI) and integrated discrimination improvement (IDI) analyses indicated that RM2 had improvement in predicting POLE mutation status when compared with the single-sequence-based signatures and the radiomics model1 (RM1). The calibration curve, decision curve analysis, and clinical impact curve suggested favourable calibration and clinical utility of RM2.
Conclusions
The RM2, fusing features from three sequences, could be a potential tool for the non-invasive preoperative identification of patients with POLE-mutant EC, which is helpful for developing individualized therapeutic strategies. Advances in knowledge: This study developed a potential surrogate of POLE sequencing, which is cost-efficient and non-invasive.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Radiology, Jinshan Hospital, Fudan University, Shanghai, China.
- Department of Radiology, Fudan University Shanghai Cancer Center, Shanghai, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
- Department of Pathology, Obstetrics & Gynecology Hospital, Fudan University, Shanghai, China.
- Department of Gynecological Oncology, Fudan University Shanghai Cancer Canter, Shanghai, China.
- Department of Radiology, Shanxi Province Cancer Hospital, Shanxi Medical University, Taiyuan, China.
ORCID-Profile: Jinwei Qiang
Zitieren
APA
Lin, Z., Gu, W., Guo, Q., Xiao, M., Li, R., Deng, L., Li, Y., Cui, Y., Li, H., & Qiang, J. (2023). Multisequence MRI-based radiomics model for predicting POLE mutation status in patients with endometrial cancer. The British Journal of Radiology. https://doi.org/10.1259/bjr.20221063
Vancouver
Lin Z, Gu W, Guo Q, Xiao M, Li R, Deng L, et al. Multisequence MRI-based radiomics model for predicting POLE mutation status in patients with endometrial cancer. The British Journal of Radiology. 2023. doi:10.1259/bjr.20221063
BibTeX
@article{Lin2023,
author = {Lin, Zijing and Gu, Weiyong and Guo, Qinhao and Xiao, Meiling and Li, Rong and Deng, Lin and Li, Ying and Cui, Yanfen and Li, Haiming and Qiang, Jinwei},
title = {Multisequence MRI-based radiomics model for predicting POLE mutation status in patients with endometrial cancer},
journal = {The British Journal of Radiology},
year = {2023},
doi = {10.1259/bjr.20221063}
}
EUVIMED